Sanofi's New Rare Disease Therapies Receive Expert Recommendation in India
Sanofi has received a Subject Expert Committee recommendation for new Pompe and ASMD therapies in India, announced on Rare Disease Day. The company has supported rare disease efforts in the country for 13 years.
Sanofi has announced a significant step forward in rare disease treatment in India, marking the occasion of Rare Disease Day. The company confirmed that a Subject Expert Committee has recommended new therapies for Pompe disease and Acid Sphingomyelinase Deficiency (ASMD).
This development underscores Sanofi's ongoing commitment to empowering patients with rare diseases by providing transformative healthcare options. The pharmaceutical giant has been a consistent supporter of Rare Disease Day initiatives in India for the past 13 years, demonstrating a long-term dedication to the cause.
Sanofi has a history of bringing treatments for various rare conditions to market, including therapies for Gaucher disease, Fabry disease, and Mucopolysaccharidosis I (MPS I). The company has also focused on increasing awareness, providing diagnostic support, and building clinical capacity for rare diseases within India.
Key initiatives include the "Disha" diagnostic program, which has provided free testing for over 6,000 suspected rare disease cases since 2013. Additionally, the "Pratigya" patient support program offers free home infusion services for patients undergoing treatment.
Sanofi's global humanitarian program provides life-saving treatment to patients in need, with over 170 Indian patients currently benefiting from the program, which enables individuals, including children, to lead near-normal lives.